Knight Therapeutics Inc. is a leading Canadian public specialty pharmaceutical company based in Montreal, Quebec that focuses on acquiring or in-licensing innovative pharmaceutical products for the Canadian and select international markets.
Knight Therapeutics Inc. (TSX:GUD) is a publicly-traded, specialty pharmaceutical company focused on acquiring, in-licensing, out-licensing, marketing and distributing innovative prescription pharmaceuticals, consumer health products and medical devices in Canada and Latin America.
In addition, Knight invests in or finances other life sciences companies with the goal of securing product distribution rights. Knight has acquired or in-licensed a portfolio of over 20 products that are marketed, under regulatory review or in various stages of development. Knight is headquartered in Montreal, Quebec, Canada and has over 45 employees.
It is listed on the Toronto Stock Exchange (symbol GUD), with a market capitalization of $1.02 billion as of August 2019.
Traded as: TSX: GUD; S&P/TSX Composite Component
Founder: Jonathan Goodman and Marc Beaudet
Headquarters: Montreal, Quebec, Canada